Memantine Hcl
Rank #140 of 500 drugs by total cost
Data: CMS Medicare Part D, 2023 (most current available) · Updated March 2026
$117.5M
Total Cost
2,268,098
Total Claims
$117.5M
Total Cost
42,973
Prescribers
$52
Cost per Claim
329,165
Beneficiaries
3,377,638
30-Day Fills
$2,735
Avg Cost/Provider
53
Avg Claims/Provider
Share of Medicare Part D Spending
0.04%
of total Medicare Part D spending
$117.5M of $275.65B
Top Prescribers by Cost
Top 10 prescribers of $117.5M total
Top Prescribers of Memantine Hcl
| # | Provider | Specialty | Location | Claims | Cost |
|---|---|---|---|---|---|
| 1 | Daniel Chang | Neurology | Los Angeles, CA | 2,262 | $635K |
| 2 | Sang Baik | Internal Medicine | Los Angeles, CA | 629 | $272K |
| 3 | Bosheng Qiu | Internal Medicine | Alhambra, CA | 984 | $186K |
| 4 | Vlad Nusinovich | Internal Medicine | West Hollywood, CA | 609 | $175K |
| 5 | Arutyun Topsakalyan | General Practice | Glendale, CA | 896 | $172K |
| 6 | Robert Morton | Psychiatry | Ada, OK | 2,586 | $172K |
| 7 | Gennadiy Goldvekht | Nurse Practitioner | Brooklyn, NY | 896 | $164K |
| 8 | Elvira Kamenetsky | Neurology | Brooklyn, NY | 795 | $154K |
| 9 | Valentin Bragin | Psychiatry & Neurology | Brooklyn, NY | 857 | $152K |
| 10 | Teresa Castro Ponce | Neurology | Guaynabo, PR | 1,305 | $144K |
| 11 | Anahit Blikian | General Practice | Glendale, CA | 834 | $139K |
| 12 | Terence Frinks | Family Practice | Tucker, GA | 3,255 | $137K |
| 13 | Jung Bae | Internal Medicine | Los Angeles, CA | 534 | $132K |
| 14 | Hector Santos | Neurology | Carolina, PR | 835 | $129K |
| 15 | Marina Neystat | Neurology | Forest Hills, NY | 708 | $125K |
Top prescribers ranked by total cost for this drug in 2023.
Related Drugs by Cost
| # | Drug | Total Cost | Claims |
|---|---|---|---|
| 137 | Insulin Regular, Human (Afrezza) | $119.4M | 143,017 |
| 138 | Ezetimibe (Ezetimibe) | $118.1M | 2,859,001 |
| 139 | Ambrisentan (Ambrisentan) | $117.7M | 23,927 |
| 140 | Memantine Hcl (Memantine Hcl) | $117.5M | 2,268,098 |
| 141 | Estradiol (Estradiol) | $115.7M | 1,412,386 |
| 142 | Vortioxetine Hydrobromide (Trintellix) | $113.9M | 197,873 |
| 143 | Asfotase Alfa (Strensiq) | $113.8M | 1,142 |
Related Analysis
Data from CMS Medicare Part D Prescriber-Drug Public Use File, 2023. Methodology